Kyung-Do Ki

Kyung-Do Ki

Auto-generated profile, based on publicly available information

Kyung-Do Ki

Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KLKwang-Beom Lee
Kwang-Beom Lee
KKKyung-Do Ki
Kyung-Do Ki
JLJong-Min Lee
Jong-Min Lee
JLJae-Kwan Lee
Jae-Kwan Lee
HKHak Jae Kim
Hak Jae Kim
KKKi-Tae Kim
Ki-Tae Kim

5 June 2009 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MLMyong Cheol Lim
Myong Cheol Lim
SKSokbom Kang
Sokbom Kang
SSSang-Soo Seo
Sang-Soo Seo
SKSun-Young Kong
Sun-Young Kong
BLBo-Yon Lee
Bo-Yon Lee
SPSang-Yoon Park
Sang-Yoon Park

1 January 2017 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MLMyong Cheol Lim
Myong Cheol Lim
MLMaria Lee
Maria Lee
SSSeung-Hyuk Shim
Seung-Hyuk Shim
ENEun Ji Nam
Eun Ji Nam
JLJung-Yun Lee
Jung-Yun Lee
JLJong-Min Lee
Jong-Min Lee
Lim MC, et al. J Gynecol Oncol. 2017 Mar;28(3):e22. https://doi.org/10.3802/jgo.2017.28.e22

1 May 2010 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
STSeo‐Yun Tong
Seo‐Yun Tong
KKKyung‐Do Ki
Kyung‐Do Ki
JLJong‐Min Lee
Jong‐Min Lee
MKMin‐Ju Kang
Min‐Ju Kang
THTae‐Kyu Ha
Tae‐Kyu Ha
SLSeon‐Kyung Lee
Seon‐Kyung Lee
To explore the implication of human SRBC gene [serum deprivation response factor-related gene product that binds to the c-kinase (hSRBC)] abnormality in ovarian tumorigenesis. Retrospective study. Medical center. Twenty-two epithelial ovarian cancer and six normal ovary tissues. Mutation and altered expression of hSRBC gene. hSRBC expression was characterized by polymerase chain reaction (PCR) analysis. Promoter CG dinucleotide (CpG) site methylation was determined using methylation specific PCR and bisulfite sequencing. Expression of hSRBC transcript was easily detectable in all normal tissues we examined, but 50% (two of four) of cancer cell lines and 41% (nine of 22) of primary carcinomas exhibited undetectable or substantially decreased expression. While genomic deletion or somatic mutations of the gene was not identified, its expression was reactivated in tumor cells by 5-aza-2'-deoxycytidine treatment, suggesting epigenetic inactivation of the gene in tumors. Promoter methylation was detected in all nine tumors with low expression but in only one of 13 (7.7%) tumors with normal expression. Bisulfite DNA sequencing analysis of 23 CpG sites within the promoter region revealed that the CpG sites are highly methylated in low-expressing tumors. In addition, promoter CpG sites methylation status showed a tight association with gene expression level. Our data demonstrate that epigenetic inactivation of hSRBC due to aberrant promoter hypermethylation is a common event and might be implicated in human ovarian tumorigenesis.

1 January 2014 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
HSHyun-Joo Seol
Hyun-Joo Seol
RURoshani Ulak
Roshani Ulak
KKKyung-Do Ki
Kyung-Do Ki
JLJong-Min Lee
Jong-Min Lee
Cervical cancer is the third most common malignant disease of women worldwide. Despite advances in screening and treatment strategies, a significant number of patients have advanced and recurrent disease. These patients are not amenable to curative treatments, such as surgery and radiation, and have poor prognosis. Therefore, palliative treatment remains the standard of care for these patients. Several phase II/III trials have demonstrated that cisplatin is the most active single agent, and the combination of cisplatin and paclitaxel is considered a standard regimen for clinical practice and trials in these patients with improved response rates and progression-free intervals. Although other cisplatin doublet chemotherapy regimens were not superior to cisplatin plus paclitaxel, substituting topotecan or gemcitabine for paclitaxel might be helpful for some patients considering different toxicity profiles. Because the response to palliative chemotherapy is poor, several targeted agents including bevacizumab, erlotinib, pazopanib, lapatinib, sunitinib and cetuximab, each of which inhibits cell proliferation and angiogenesis, were evaluated in these patients. Of them, bevacizumab, targeting vascular endothelial growth factor, showed favorable results. Recent phase III trial showed that bevacizumab combined with chemotherapy was shown to significantly improve the response rate, progression-free interval, and overall survival compared to chemotherapy alone. These results suggest that targeted agents could significantly improve survival and affect practice guidelines in these patients showing poor prognosis. Thus, future trials using newly developed targeted agents are warranted to improve treatment strategies in these patients.

1 August 2008 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
KLK.-B. Lee
K.-B. Lee
JLJong-Min Lee
Jong-Min Lee
KKK.-D. Ki
K.-D. Ki
SLS.-K. Lee
S.-K. Lee
CPC.-Y. Park
C.-Y. Park
SHS.-Y. Ha
S.-Y. Ha